This increase could be reversed by the simultaneous expression of a dominant-negative TP53 allele, suggesting that PP2A exerts its tumor-inhibiting effect via the p53 signaling pathways within the PI3K/AKT axis. The gene discussed is TP53; the disease is neoplasm.